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Background: Non-small cell lung cancers (NSCLCs) are frequently heterogeneous and in approximately 70% of
cases, NSCLCs are diagnosed and staged by small biopsies or cytology rather than by examination of surgically
resected specimens. Thus, in most patients, the diagnosis is established based on examination of preoperative
specimens alone. Recently, classification of NSCLC into pathologic subtypes has been shown to be important for
selecting the appropriate systemic therapy, from both the point of view of treatment efficacy and prevention of toxicity.
Methods: We retrospectively reviewed the data of 225 patients to compare the preoperative classification of the NSCLC
subtype on biopsy specimens with the postoperative classification based on examination of the resected specimens, in
order to compare the accuracy of the two for the diagnosis of various histological subtypes of NSCLC.
Results: In 169 of the 225 (75.1%) patients, the preoperative diagnosis was definite malignancy. Histologically, the final
pathologic diagnosis made from the surgical specimens was adenocarcinoma (ADC) in 169 patients, and in 75.5% of
these cases, the diagnosis was concordant with the preoperative diagnosis. Among the patients who had squamous cell
carcinoma (SQC) in the preoperative specimens, the diagnosis was concordant with the preoperative diagnosis in 65.7%
of cases. Misclassified preoperative biopsies included an even number of SQCs and ADCs, with all the misclassified
biopsies being ADCs morphologically mimicking SQC due to solid growth. Significantly higher specificity, negative
predictive value and accuracy were observed for the diagnosis of SQC.
Conclusions: Our study suggested that the concordance rates for diagnosis of the NSCLC subtypes, especially the
“squamous” or “non-squamous” histologies, between preoperative and surgical specimens were satisfactory, as
compared with previous reports. Therefore, pretreatment diagnosis of lung cancer using small samples is reasonable for
selecting the optimal treatment. However, in order not to lose the opportunity for selecting an effective treatment, we
should be aware that the diagnosis in preoperative small samples might be different from that based on examination of
the surgical specimens.
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Lung cancer is the leading cause of cancer and mortality
from cancer worldwide [1], with 5-year survival rates
of <15% across all stages of the disease [2]. Historically,
lung cancer is divided into two morphologic types: small
cell lung cancer and non-small-cell lung cancer (NSCLC),
with NSCLC accounting for approximately 80% to 85% of
all histological types of NSCLC [3].
The International Association for the Study of Lung
Cancer, the American Thoracic Society, and the European
Respiratory Society recently proposed the classification of
NSCLC based on examination of small biopsy and/or
cytology specimens into six main subtypes: adenocarcin-
oma (ADC), squamous cell carcinoma (SQC), NSCLC not
otherwise specified (NSCLC-NOS), NSCLC with neuroen-
docrine morphology, NSCLC with squamous and adeno-
carcinoma patterns, and poorly differentiated NSCLC
with spindle and/or giant cell carcinoma [4]. NSCLCs
are frequently heterogeneous and approximately 70% of
NSCLCs are diagnosed and staged by examination of
small biopsy or cytology specimens rather than by
examination of surgically resected specimens [5]; thus,
in most patients, the diagnosis is based on examination
of preoperative specimens alone. Until now, histological
subtyping of NSCLC was not considered to be clinically
or therapeutically important, because of the lack of ex-
istence of differential treatment options for the various
subtypes of NSCLC. However, there is now clearFigure 1 A case with discordant diagnosis of the histological subtype
tomographic image showing a mass lesion measuring 4 cm in diameter in th
was performed. Pathological findings of the biopsy specimen showed keratin
(C-D) Surgically resected specimen showing both a squamous and glandular
carcinoma (H.E. stain, ×100).evidence to suggest that the classification of NSCLC
into pathologic subtypes is important for the selection
of appropriate systemic therapy, from both the point of
view of treatment efficacy and prevention of toxicity
[6,7]. For example, large phase III clinical trials have
demonstrated that ADC is a strong predictive factor for
improved outcome following treatment with the com-
bination of pemetrexed with cisplatin compared with
SQC [8]. In addition, the presence of common activat-
ing mutations in the tyrosine kinase domain of the epi-
dermal growth factor receptor (EGFR) gene (exon 19
deletion and exon 21 L858R mutation) confers strong
sensitivity to gefitinib and erlotinib, which are selective
tyrosine kinase inhibitors of EGFR [9,10]. These EGFR
mutations are more commonly encountered in ADCs
[11]. Furthermore, the use of vascular endothelial
growth factor (VEGF) inhibitors (eg, bevacizumab) has
been demonstrated to be associated with an increased risk
of fatal pulmonary hemorrhage in patients with SQC [12].
The ALK tyrosine inhibitor crizotinib was demonstrated
to show marked antitumor activity in NSCLC patients
with EML4-ALK translocation, observed in approximately
3 to 4% of patients with ADC [13]. Thus, a molecular test-
ing guideline has been proposed [14].
If pathological findings are missed, especially when
differentiating between “squamous” and “non-squamous”
histology, determination of the appropriate treatment is
difficult. The aim of this study was to compare thebetween preoperative and surgical specimens. (A) Computed
e left upper lobe. (B) Computed tomography-guided fine needle biopsy
ized cells, suggestive of squamous cell carcinoma (H.E. stain, ×100).
component, suggesting the postoperative diagnosis of adenosquamous
Table 1 Patient characteristics (n = 225)
Variable Number %
Age, mean ± SD 69.0 ± 10.2
Sex
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specimens with the postoperative classification made on
the basis of examination of resected specimens, and to
examine how often accuracy about each histological sub-














Between April 2004 and June 2011, 442 patients under-
went surgical resection for lung cancer at Kawasaki
Medical School Hospital, Kurashiki, Japan. We retro-
spectively reviewed the data of a consecutive series of
225 (50.9%) patients in whom preoperative diagnosis
was made by transbronchial biopsy (TBB) or computed
tomography-guided fine needle biopsy (CTNB). For
each patient, the clinical information at diagnosis was
collected from the medical records. This study was con-
ducted with the approval of the institutional Ethics
Committee of Kawasaki Medical School (No.887).IIIA 36 15.9
IIIB/IV 11 4.9
Abbreviations: NSCLC-NOS Non–small-cell lung carcinoma not otherwise specified.





ADC SQC NSCLC-NOS ASC PLE Total
Malignant
ADC 105 3 2 3 2 115
SQC 44 1 45
NSCLC-NOS 2 1 4 7
PLE 2 2
Suspicious of NSCLC 5 7 1 13
Not malignant 27 12 3 1 43
Total 139 67 10 4 5 225
Abbreviations: ADC adenocarcinoma, SQC squamous cell carcinoma NSCLC-NOS
non-small-cell lung cancer not otherwise specified, ASC adenosquamous
carcinoma, PLE pleomorphic carcinoma.Transbronchial biopsy and computed tomography-guided
fine needle biopsy procedures
While TBB is commonly performed in the diagnostic
workup of pulmonary peripheral nodules, CTNB is usu-
ally performed either when the tumor is not detected
bronchoscopically or when it is thought unlikely to be
accessible by bronchoscopy. Flexible bronchoscopy is
conducted by experienced bronchoscopists, while CTNB
is performed by interventional radiologists, with standard
techniques for both. All aspirated materials and biopsy
specimens were fixed in formalin and embedded in paraf-
fin, and sections are routinely stained with hematoxylin
and eosin (H&E). Cytological examinations of sputum, as-
pirated material and bronchial brushings, and washing
were not included in the diagnostic workup in this study,
because the aim of the study was histological comparison
between preoperative biopsy specimens and surgically
resected specimens.
The results of the examination of the small diagnostic
specimens were classified as no malignancy, suspected
malignancy or definite malignancy. Furthermore, definite
malignancy of NSCLC was classified into ADC, SQC,
NSCLC or other histological subtypes (others). If there
is no clear ADC or SQC morphology, the tumor can be
further classified based on immunohistochemocal stains
(IHC) and mucin (periodic acid Schiff ) stains. If the
stains all favor ADC: positive ADC markers (i.e., TTF-1
and/or mucin positive) with negative SQC markers, then
the tumor is classified as ADC. If SQC markers (i.e., p63)
are positive with negative ADC markers, the tumor is clas-
sified as SQC. If the ADC and SQC markers are both
strongly positive and negative, the tumor is classified as
NSCLC-NOS and others.Statistical analysis
Sensitivity, specificity, positive predictive value (PPV),
negative predictive value (NPV), and accuracy were calcu-
lated according to the standard definitions for the diagno-
sis of lung cancer and malignancy. Continuous variables
were analyzed by the Student's t-test, and the results were
expressed as mean ± standard deviation (SD). Dichotom-
ous variables were analyzed by the Fisher's exact test or
the χ2 test, as appropriate. Discontinuous variables were
coded as dummy variables. Two-sided p-values of less
than 0.05 were considered to be statistically significant.
All analyses were performed using the SPSS software
(Version 17.0; SPSS Incorporation, Chicago, IL).
Table 3 Diagnostic value of preoperative diagnosis between adenocarcinoma and squamous cell carcinoma
Sensitivity Specificity PPV NPV Accuracy
(%) (%) (%) (%) (%)
Lung cancer 75.1 - 100 100 75.1
(169/225) (169/169) (56/56) (169/225)
ADC 75.5 88.3 91.0 69.0 80.4
(105/139) (76/86) (105/115) (76/110) (181/225)
SQC 65.6 99.3 97.7 87.2 89.3
(44/67) (157/158) (44/45) (157/180) (201/225)
p-value (ADC vs. SQC) 0.138 <0.001 0.184 <0.001 0.012
Abbreviations: PPV Positive predictive value, NPV Negative predictive value, ADC adenocarcinoma, SQC squamous cell carcinoma.
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Case report
A 74-year-old woman who was a never-smoker was re-
ferred to our hospital because of hoarseness. Computed
tomography showed a solid mass approximately 4 cm in
diameter in the left upper lobe associated with mediastinal
lymphadenopathy (Figure 1A). CTNB was carried out, and
biopsy examination confirmed a well-keratinized tumor
without obvious glandular features or cytoplasmic mucin
(Figure 1B). The patient was diagnosed as having SQC of
the lung, stage IIIA (T2aN2M0). Left upper lobectomy
with mediastinal lymph node dissection was performed.
Both ADC and SQC components were observed in the
pathological specimen, suggesting the postoperative diag-
nosis of adenosquamous carcinoma (Figure 1C&D). One
year later, recurrence was found in the form of mediastinal
lymphadenopathy. We performed a molecular analysis of
the surgical specimens, which revealed an EGFR gene mu-
tation, and treatment with oral gefitinib was initiated. The
patient would have lost the opportunity to receive gefitinib
treatment if had just been diagnosed as having inoperable
advanced NSCLC, because the molecular testing guideline
does not recommend EGFR mutation analysis in patients
with SQC [14].
Patient characteristics
A total of 225 patients (159 men and 66 female; mean
age, 69.0 ± 10.2 years) were enrolled in this study. The







SQC 2 40 6
Unclassified 5 2 7
Total 86 42 41
Abbreviations: ADC adenocarcinoma, SQC squamous cell carcinoma, NSCLC-NOS non
H&E hematoxylin and eosin, IHC immunohistochemistry.pathological examination are shown in Table 1. The
most frequent histological type was ADC; 139 (61.5%)
had ADC, 67 (30.1%) had SQC, 10 (4.4%) had large cell
carcinoma, and 9 (4.0%) had others (other subtypes).
The patients were classified according to the histopatho-
logical stage as follows: 131 patients had stage I, 47 had
stage II, and 47 had stage III or IV disease. Most stage
III and IV patients were recognized during and after sur-
gery due to mediastinal lymph node metastasis (cN0-
pN2) and pleural dissemination (cM0-pM1a). A few
stage III patients were performed resection due to single
mediastinal lymph node metastasis.
Sensitivity of preoperative diagnosis for the detection
of NSCLC
The preoperative diagnosis was compared with the final
pathological findings (Table 2). In 169 of the 225 (75.1%)
patients, the preoperative diagnoses were definite malig-
nancy (115 ADC, 45 SQC, 2 large cell carcinoma, 2
pleomorphic carcinoma, and 5 NSCLC). In 56 of the
225 (24.9%) patients, the preoperative specimens showed
suspected or no malignancy: while NSCLC was suspected
preoperatively in 13 of these patients, no malignancy was
suspected in 43 patients. The overall sensitivity for the de-
tection of lung cancer was 75.1%.
Histologically, the final pathological examination of the
surgical specimens revealed ADC in 139 patients, of
whom in 105 (75.5%) patients, the diagnosis was concord-
ant with the preoperative diagnosis. Of the remaining 34reoperative diagnosis
IHC predicted phenotype
Total ADC SQC Unclassified Total
107 26 26
48 1 3 4
14 2 3 5
169 29 3 3 35
-small-cell lung cancer not otherwise specified, PLE pleomorphic carcinoma,
Squamous patter n
(i.e., intracellular bridge s
or keratini za tion )
Glandular patter n













(i.e., p63 posi ti ve)
Favor ADC







IHC and PAS sta in
n=35
76% subtyped
(79% accuracy - ADC)
(94% accuracy - SQC)
19% subtyped
(91% accuracy - ADC)
(97% accuracy - SQC)








Figure 2 Diagnostic algorism for classification of NSCLC in preoperative specimens.
Yamagishi et al. Diagnostic Pathology 2014, 9:103 Page 5 of 8
http://www.diagnosticpathology.org/content/9/1/103patients, 2 patients had NSCLC, 5 patients had suspected
NSCLC, and 27 patients had no malignancy. In all, 67 pa-
tients had SQC of the lung on the preoperative specimens,
and in 44 (65.7%) of these patients, the diagnosis was con-
cordant with the preoperative diagnosis. Among the 23 of
the remaining 67 (34.3%) with a discordant diagnosis, 3
patients had ADC, 1 patient had NSCLC, 7 patients had
suspected NSCLC and 12 patients had no evidence of ma-
lignancy. Misclassified preoperative biopsies included an
even number of SQCs and ADCs (n = 3), whereas all of
the misclassified biopsies were ADC, morphologically
mimicking SQC due to the solid growth.
We compared the sensitivity, specificity, predictive
values and accuracy for the diagnosis of ADC and SQC(Table 3). Significantly higher specificity, NPV and accur-
acy were observed for SQC (p < 0.05).
Comparison of H&E stain vs. IHC for subtyping NSCLC
For the comparison of H&E stain vs IHC, 169 patients
were included, all of whom underwent H&E stain. Among
them, IHC was performed on 35 (21%) patients (Table 4).
As summarized in Figure 2, 128 of 169 patients (76%) were
specifically subtyped on the H&E stain as either ADC or
SQC. 41 (24%) patients were not subtyped on the H&E
stain sections. IHC could successfully subtype NSCLC
in 32 of 35 cases (29 ADC, 3 SQC). The remaining three
cases were not still subtyped (2 NSCLC-NOS, 1 PLE).
However, by combining the results of the two methods,
Table 5 Comparison of TBB vs. CTNB for sensitivity/concordance rate
Histological diagnosis
Lung cancer Suspicious of malignancy No malignancy Sensitivity p-value Concordance p-value
TBB 140 13 37 73.2 (140/190) 0.249 66.8 (127/190) 0.594
CTNB 29 0 6 82.9 (29/35) 71.4 (25/35)
Total 169 13 43 75.0 (169/225) 67.6 (152/225)
Abbreviations: TBB Transbronchial biopsy, CTNB Computed tomography-guided fine needle biopsy.
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was reduced to 9 (5%) patients. The accuracy of both
morphologic differentiation and IHC based predictive
subtype is <100% (Figure 2).
Comparison of TBB vs. CTNB for the sensitivity or
concordance of lung cancer diagnosis
Among the 225 patient studied, TBB was performed in
190 patients. Of these, 140 (73.7%) were diagnosed as hav-
ing definite lung cancer, 13 (6.8%) were suspected as hav-
ing malignancy, and 37 (19.5%) were diagnosed as having
no malignancy. CTNB was performed in 35 patients. Of
these, 29 (82.9%) and 6 (17.1%) cases were diagnosed as
having lung cancer and no malignancy, respectively. Thus,
there was no significant difference in the level of diagnos-
tic certainty between TBB and CTNB (Table 5).
Comparison of the sensitivity or concordance rate of the
histological type between preoperative and surgical
specimens in relation to the tumor size
The results of detection of lung cancer were correlated
with the tumor size. The overall sensitivity and concord-
ance rate of histological type between preoperative biop-
sies and surgical specimens were 75.1% (169/225) and
67.6% (152/225). The sensitivity rate was correlated with
the tumor size. The diagnostic sensitivity of lesions lar-
ger than 2.1 cm in diameter was significantly better than
that of lesions less than 2 cm in diameter (p = 0.001,
Table 6). However, concordance rate was not correlated
with the tumor sizes.
Discussion
We assessed the accuracy of diagnosis of the histological
type of lung cancer between preoperative and surgical
specimens. The reported accuracy for bronchoscopic bi-
opsy as compared to histopathology of resected or aut-
opsy specimens for differentiating among histologicalTable 6 Comparison between tumor size and sensitivity/conc
Histological diagnosis
Lung cancer Suspicious of malignancy No malign
<=2 cm 30 0 19
>2 cm 139 13 24
Total 169 13 43subtypes of lung cancer is in the range of 62% to 97.5%
[15-19]. In our study, the concordance rates for diagno-
sis of the NSCLC subtypes between preoperative biop-
sies and histopathology of surgical specimens was 66.8%
(127/190), which seemed to be slightly low as compared
to previous reports; however, many studies excluded tu-
mors that were confirmed as not being malignant: in our
study, 50 (26.3%) of 190 patients were diagnosed as not
having malignant lesions before excision. After patients
without malignancies as determined in preoperative
specimens were excluded, the concordance rate was
90.7% (127/140). We found a better accuracy for the
diagnosis of SQC than for that of ADC (89.3% vs. 80.4%,
p = 0.012), which was also in agreement with previous
studies [13,20]. On the other hand, the sensitivity for
ADC was slightly better than that for SQC (75.7% vs.
65.6%, p = 0.138), indicating that ADC seems to have lit-
tle oversight by preoperative specimens.
IHC studies are usually required if obvious morpho-
logical features of squamous or glandular differentiation
are not identified. Similar to the findings of this study,
prior studies found that ~75% of bronchial NSCLC sam-
ples may be subtyped using morphology alone, and 93%
of all NSCLC cases may be subtyped when combined
immunostaining [21]. Other studies also demonstrated
that only a low population (6%) of cases remained with-
out a probable subtype after morphologic examination
and IHC [22]. The low not-typed rate in these studies
suggests that we should perform IHC as a routine
utilization for subtyping of difficult cases.
Several factors affect the diagnostic accuracy. The fre-
quency of diagnostic errors induced by some of these
factors, including the biopsy size and degree of differen-
tiation has been described [20]. In our study, the tumor
size was correlated with the sensitivity and concordance
rate: the larger the diameter, the greater the sensitivity
and cell type agreement.ordance rate
ancy Sensitivity p-value Concordance p-value
61.2 (30/49) 0.011 57.1 (28/49) 0.078
78.9 (139/176) 70.4 (124/176)
75.0 (169/225) 67.6 (152/225)
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on the histological subtype of lung cancer (SQC vs. non-
SQC) and its molecular characteristics (e.g., EGFR muta-
tion and ALK rearrangement states). Furthermore, many
previous studies showed the expression and functions of
proteins and genes in lung cancer, and it may be signifi-
cantly related to tumor progression and metastasis [23-26].
Both EGFR mutation and ALK rearrangements are al-
most exclusively seen in ADC. According to multiple
large phase III crinical trials [11,27-29], the new classifi-
cation recommends that all patients with advanced lung
ADC be tested for EGFR mutation, as EGFR tyrosine
kinase inhibitors can be used as first-line chemotherapy
for patients with EGFR mutations. Crizotinib has been
approved by the US Food and Drug Administration
(FDA) for advanced ADC with ALK rearrangements
[30]. Therefore, testing for EGFR mutations and ALK re-
arrangements in patients with advanced ADC is no lon-
ger only a research tool, and should be performed in
clinical practice. On the other hand, several molecular
targets such as FGFR1 amplification and DDR2 mutation
have been discovered in SQC [31,32]. Target therapies
that might be beneficial in this selected subpopulation
have never been reported. These results indicate that
misdiagnosis of ADC as SQC in preoperative specimens
should be avoided so as to prevent the loss of opportun-
ity to select beneficial molecular-targeted therapy for
these patients in clinical practice. Although such a result
was not seen, there were three (1.3%) misclassifications
between ADC and SQC in the preoperative specimens,
and in all, SQC was diagnosed as ADC. Fortunately,
there was only a lone patient who might have lost the
opportunity to receive EGFR-TKI therapy by missed
diagnosis (0.44%, shown as case report).
Our retrospective study had some limitations. First,
only half of the patients who underwent surgery received
preoperative diagnosis by TBB or CTNB. Second, there
may be variability between intra- and inter- pathologist
in lung cancer diagnosis. Because a smaller amount of
tissue is obtained, the diagnostic assessment might be
more difficult and more inconsistencie in the diagnosis
of pathologists might occur. In such cases, multidiscip-
linary approach and expert consultation are recom-
mended [33].
Conclusions
In conclusion, our study suggested that the concordance
rate for the diagnosis of NSCLC subtypes, especially
“squamous” or “non-squamous” histology, between pre-
operative and surgical specimens was satisfactory as
compared with other reports. Pretreatment diagnosis of
lung cancer using small samples is reasonable for selec-
tion of the optimal treatment. However, our case report
presented above serves to emphasize the need to beaware that diagnosis based on preoperative small sam-
ples might be different from that made from surgical
specimens, so as to not lose the opportunity for effective
treatment.
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